Total Payments
$43,469
2024 Payments
$726.92
Companies
34
Transactions
801
Medicare Patients
2,145
Medicare Billing
$568,873
Payment Breakdown by Category
Research$22,417 (51.6%)
Food & Beverage$14,295 (32.9%)
Other$6,440 (14.8%)
Education$316.24 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,417 | 19 | 51.6% |
| Food and Beverage | $14,295 | 765 | 32.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,440 | 7 | 14.8% |
| Education | $316.24 | 10 | 0.7% |
Payments by Type
Research
$22,417
19 transactions
General
$21,051
782 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $13,125 | 9 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $7,050 | 59 | $0 (2021) |
| Eli Lilly and Company | $6,819 | 8 | $0 (2023) |
| ABBVIE INC. | $2,012 | 94 | $0 (2024) |
| Allergan, Inc. | $1,951 | 80 | $0 (2020) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,632 | 9 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $1,620 | 77 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,204 | 65 | $0 (2024) |
| Lundbeck LLC | $1,055 | 59 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $932.80 | 45 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $726.92 | 35 | ABBVIE INC. ($306.27) |
| 2023 | $3,071 | 112 | Eli Lilly and Company ($968.50) |
| 2022 | $7,449 | 106 | Eli Lilly and Company ($5,139) |
| 2021 | $4,926 | 114 | Sunovion Pharmaceuticals Inc. ($2,100) |
| 2020 | $3,269 | 86 | Sunovion Pharmaceuticals Inc. ($1,750) |
| 2019 | $6,609 | 151 | Sunovion Pharmaceuticals Inc. ($2,963) |
| 2018 | $6,814 | 91 | ACADIA Pharmaceuticals Inc ($5,023) |
| 2017 | $10,603 | 106 | ACADIA Pharmaceuticals Inc ($8,000) |
All Payment Transactions
801 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $27.68 | General |
| Category: PSYCHIATRY | ||||||
| 08/28/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.80 | General |
| Category: PSYCHIATRY | ||||||
| 06/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.17 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: PSYCHIATRY | ||||||
| 06/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: NEUROSCIENCE | ||||||
| 06/05/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Neurology | ||||||
| 05/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: Psychology/Psychiatric | ||||||
| 05/22/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.53 | General |
| Category: PSYCHIATRY | ||||||
| 05/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: NEUROSCIENCE | ||||||
| 05/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.60 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: PSYCHIATRY | ||||||
| 05/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.70 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: Neurology | ||||||
| 03/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: NEUROSCIENCE | ||||||
| 03/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: NEUROSCIENCE | ||||||
| 03/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: CNS | ||||||
| 03/07/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Central Nervous System | ||||||
| 03/01/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $29.21 | General |
| Category: BH | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $13,000 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $4,839 | 2 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,606 | 8 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $1,016 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $948.59 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $668.50 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $39.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 385 | 628 | $114,900 | $57,074 |
| 2022 | 4 | 360 | 808 | $105,289 | $70,504 |
| 2021 | 6 | 669 | 2,339 | $311,172 | $233,852 |
| 2020 | 9 | 731 | 2,286 | $346,431 | $207,444 |
Total Patients
2,145
Total Services
6,061
Medicare Billing
$568,873
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 120 | 235 | $42,300 | $17,911 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 97 | 145 | $29,000 | $16,490 | 56.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 115 | $17,250 | $9,639 | 55.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $8,100 | $4,125 | 50.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 39 | 66 | $8,250 | $3,938 | 47.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $5,750 | $3,503 | 60.9% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2023 | 17 | 17 | $4,250 | $1,468 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 160 | 387 | $60,787 | $38,513 | 63.4% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 168 | 380 | $38,632 | $27,385 | 70.9% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2022 | 19 | 28 | $3,211 | $2,532 | 78.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $2,659 | $2,075 | 78.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 261 | 1,048 | $164,369 | $124,891 | 76.0% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 276 | 1,123 | $114,291 | $89,608 | 78.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 70 | 85 | $21,250 | $10,918 | 51.4% |
| 90847 | Family psychotherapy including patient, 50 minutes | Office | 2021 | 27 | 48 | $5,556 | $4,404 | 79.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $4,705 | $3,260 | 69.3% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 12 | 12 | $1,001 | $771.60 | 77.1% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 260 | 1,002 | $118,972 | $78,044 | 65.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 168 | 653 | $93,372 | $62,163 | 66.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 138 | 391 | $95,825 | $48,246 | 50.3% |
| 90834 | Psychotherapy, 45 minutes | Office | 2020 | 58 | 95 | $19,000 | $6,408 | 33.7% |
| 90847 | Family psychotherapy including patient, 50 minutes | Office | 2020 | 37 | 65 | $8,723 | $5,731 | 65.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 17 | 17 | $3,475 | $2,397 | 69.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 25 | $2,845 | $1,563 | 55.0% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 21 | 25 | $2,438 | $1,549 | 63.5% |
About Dr. Mark Dibuono, MD
Dr. Mark Dibuono, MD is a Psychiatry healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1538143680.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Dibuono, MD has received a total of $43,469 in payments from pharmaceutical and medical device companies, with $726.92 received in 2024. These payments were reported across 801 transactions from 34 companies. The most common payment nature is "" ($22,417).
As a Medicare-enrolled provider, Dibuono has provided services to 2,145 Medicare beneficiaries, totaling 6,061 services with total Medicare billing of $568,873. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Staten Island, NY
- Active Since 12/02/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1538143680
Products in Payments
- NUPLAZID (Drug) $13,125
- LATUDA (Drug) $7,050
- VRAYLAR (Drug) $2,866
- REXULTI (Drug) $1,282
- AUSTEDO (Drug) $1,187
- CAPLYTA (Drug) $826.53
- ARISTADA (Drug) $781.42
- TRINTELLIX (Drug) $648.33
- INGREZZA (Drug) $543.95
- Trintellix (Drug) $486.69
- ABILIFY MAINTENA (Drug) $426.60
- INVEGA SUSTENNA (Drug) $304.84
- SPRAVATO (Drug) $288.00
- PERSERIS (Drug) $273.45
- Fanapt (Drug) $269.12
- MYDAYIS (Drug) $266.51
- VYVANSE (Drug) $256.20
- SUNOSI (Drug) $254.35
- APLENZIN (Drug) $215.71
- Adzenys XR-ODT (Drug) $194.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Staten Island
Dr. John Tsiouris, Md, MD
Psychiatry — Payments: $303,745
Psychiatry $303,745
Dr. Waqar Siddiqui, Md, MD
Psychiatry — Payments: $62,243
Psychiatry $62,243
Vadim Azbel, Md, MD
Psychiatry — Payments: $27,482
Psychiatry $27,482
Aruna Agni, M.d, M.D
Psychiatry — Payments: $22,355
Psychiatry $22,355
Robert Stern, Md, MD
Psychiatry — Payments: $14,172
Psychiatry $14,172
Bolaji Bankole, M.d, M.D
Psychiatry — Payments: $8,873
Psychiatry $8,873